Bladder cancer
Bladder cancer | |
---|---|
![]() | |
Transitional cell carcinoma of the bladder. The white in the bladder is contrast. | |
Specialty | Oncology, urology |
Symptoms | Blood in the urine, pain with urination[1] |
Usual onset | 65 to 84 years old[2] |
Types | Transitional cell carcinoma, squamous cell carcinoma, adenocarcinoma[1] |
Risk factors | Smoking, family history, prior radiation therapy, frequent bladder infections, certain chemicals[1] |
Diagnostic method | Cystoscopy with tissue biopsies[1] |
Treatment | Surgery, radiation therapy, chemotherapy, immunotherapy[1] |
Prognosis | Five-year survival rates ~77% (US)[2] |
Frequency | 549,000 new cases (2018)[3] |
Deaths | 200,000 (2018)[3] |
Bladder cancer is any of several types of cancer arising from the tissues of the urinary bladder.[1] Symptoms include blood in the urine, pain with urination, and low back pain.[1] It is caused when epithelial cells that line the bladder become malignant.[4]
Risk factors for bladder cancer include smoking, family history, prior radiation therapy, frequent bladder infections, and exposure to certain chemicals.[1] The most common type is transitional cell carcinoma.[1] Other types include squamous cell carcinoma and adenocarcinoma.[1] Diagnosis is typically by cystoscopy with tissue biopsies.[5] Staging of the cancer is determined by transurethral resection and medical imaging.[1][6][7]
Treatment depends on the stage of the cancer.[1] It may include some combination of surgery, radiation therapy, chemotherapy, or immunotherapy.[1] Surgical options may include transurethral resection, partial or complete removal of the bladder, or urinary diversion.[1] The typical five-year survival rates in the United States is 77%, Canada is 75%, and Europe is 68%.[2][8][9]
Bladder cancer, as of 2018, affected about 1.6 million people globally with 549,000 new cases and 200,000 deaths.[3] Age of onset is most often between 65 and 84 years of age.[2] Males are more often affected than females.[2] In 2018, the highest rate of bladder cancer occurred in Southern and Western Europe followed by North America with rates of 15, 13, and 12 cases per 100,000 people.[3] The highest rates of bladder cancer deaths were seen in Northern Africa and Western Asia followed by Southern Europe.[3]
Signs and symptoms
[edit]![](http://upload.wikimedia.org/wikipedia/commons/thumb/9/99/Blausen_0082_BladderCancer.png/290px-Blausen_0082_BladderCancer.png)
The most common symptom of bladder cancer is visible blood in the urine (haematuria) despite painless urination. This affects around 75% of people eventually diagnosed with the disease.[10] Some instead have "microscopic haematuria" – small amounts of blood in the urine that can only be seen under a microscope during urinalysis – pain while urinating, or no symptoms at all (their tumors are detected during unrelated medical imaging).[10][11] Less commonly, a tumor can block the flow of urine into the bladder, causing pain along the flank of the body (between the ribs and the hips).[12] Most people with blood in the urine do not have bladder cancer; up to 22% of those with visible haematuria and 5% with microscopic haematuria are diagnosed with the disease.[10] Women with bladder cancer and haematuria are often misdiagnosed with urinary tract infections, delaying appropriate diagnosis and treatment.[11]
People with advanced disease may have pelvic or bony pain, lower-extremity swelling, or flank pain.[13]
Diagnosis
[edit]![](http://upload.wikimedia.org/wikipedia/commons/thumb/5/5d/BladderwallthickeningduetoCaMark.png/220px-BladderwallthickeningduetoCaMark.png)
![](http://upload.wikimedia.org/wikipedia/commons/thumb/7/75/Blasentumor.jpg/220px-Blasentumor.jpg)
Those suspected of having bladder cancer can undergo several tests to assess the presence and extent of any tumors. First, many undergo a physical examination that can involve a digital rectal exam and pelvic exam, where a doctor feels the pelvic area for unusual masses that could be tumors.[14] Severe bladder tumors often shed cells into the urine; these can be detected by urine cytology, where cells are collected from a urine sample, and viewed under a microscope.[14][15] Cytology can detect around two thirds of high-grade tumors, but detects just 1 in 8 low-grade tumors.[16] Additional urine tests can be used to detect molecules associated with bladder cancer. Some detect the proteins bladder tumor antigen or NMP22 that tend to be elevated in the urine of those with bladder cancer; some detect mRNA of tumor-associated genes; some use fluorescence microscopy to detect cancerous cells more sensitively than regular cytology.[16]
Many also undergo cystoscopy, wherein a flexible camera is threaded up the urethra and into the bladder to visually inspect for cancerous tissue.[14] Cystoscopy is most sensitive to papillary tumors (tumors with a finger-like shape that grow into the urine-holding part of the bladder); it is less sensitive to small, low-lying carcinoma in situ (CIS).[17] CIS detection is improved by blue light cystoscopy, where a dye (hexaminolevulinate) that accumulates in cancer cells is injected into the bladder during cystoscopy. The dye fluoresces when the cystoscope shines blue light on it, allowing for more sensitive detection of small tumors.[14][17]
The upper urinary tract (ureters and kidney) is also imaged for tumors that could cause blood in the urine. This is typically done by injecting a dye into the blood that the kidneys will filter into the urinary tract, then imaging by computed tomography scanning. Those whose kidneys are not functioning well enough to filter the dye may instead be scanned by magnetic resonance imaging.[12]
Suspected tumors are removed by threading a device up the urethra in a process called "transurethral resection of bladder tumor" (TURBT). All tumors are removed, as well as a piece of the underlying bladder muscle. Removed tissue is examined by a pathologist to determine if it is cancerous.[14][18]
Classification
[edit]Bladder tumors are classified by their appearance under the microscope, and by their cell type of origin. Over 90% of bladder tumors arise from the cells that form the bladder's inner lining, called urothelial cells or transitional cells; the tumor is then classified as urothelial cancer or transitional cell cancer.[19][20] Around 5% of cases are squamous cell cancer (from a rarer cell in the bladder lining), particularly common in places with schistosomiasis.[20] Up to 2% of cases are adenocarcinoma (from mucus-producing gland cells).[20] The remaining cases are sarcomas (from the bladder muscle) or small-cell cancer (from neuroendocrine cells), both of which are relatively rare.[20]
The pathologist also grades the tumor sample based on how distinct the cancerous cells look from healthy cells. Bladder cancer is divided into either low-grade (more similar to healthy cells) or high-grade (less similar). High-grade cancer is further subdivided into "non-muscle-invasive bladder cancer" (NMIBC) or the more aggressive "muscle-invasive bladder cancer" (MIBC) based on whether the tumor has grown into the surrounding bladder muscle.[19]
Staging
[edit]![](http://upload.wikimedia.org/wikipedia/commons/thumb/5/5c/Diagram_showing_the_T_stages_of_bladder_cancer_CRUK_372.svg/220px-Diagram_showing_the_T_stages_of_bladder_cancer_CRUK_372.svg.png)
![](http://upload.wikimedia.org/wikipedia/commons/thumb/c/ca/Diagram_showing_stage_N1_bladder_cancer_CRUK_444.svg/220px-Diagram_showing_stage_N1_bladder_cancer_CRUK_444.svg.png)
![](http://upload.wikimedia.org/wikipedia/commons/thumb/e/e0/Diagram_showing_advanced_bladder_cancer_CRUK_441.svg/220px-Diagram_showing_advanced_bladder_cancer_CRUK_441.svg.png)
![](http://upload.wikimedia.org/wikipedia/commons/thumb/6/65/Gray611.png/220px-Gray611.png)
![](http://upload.wikimedia.org/wikipedia/commons/thumb/3/3a/Gray618.png/220px-Gray618.png)
Bladder cancer is staged (classified by the extent of spread of the cancer) and graded (how abnormal and aggressive the cells appear under the microscope) to determine treatment and predict outcomes. Staging is usually performed with transurethral resection of bladder tumor (TURBT) and radiologic imaging (CT and MRI). Papillary tumors confined to the mucosa or which invade the lamina propria are classified as Ta or T1. Flat lesions that do not invade the basement membrane of the bladder mucosa are termed Tis (in situ). All three categories (Tis, Ta and T1) are grouped together as non-muscle invasive disease for therapeutic purposes and in most cases they are offered cystoscopic resection with TURBT without the need for radical resection of the entire urinary bladder. Tumors in the remaining categories (T2, T3 and T4) are termed muscle-invasive disease and are associated with less favorable prognosis.[21]
In the TNM staging system (8th Edn. 2017) for bladder cancer:[22][23]
T (Primary tumour)
- TX Primary tumour cannot be assessed
- T0 No evidence of primary tumour
- Ta Non-invasive papillary carcinoma
- Tis Carcinoma in situ ('flat tumour')
- T1 Tumour invades subepithelial connective tissue
- T2a Tumour invades superficial muscle (inner half of the detrusor muscle)[24]
- T2b Tumour invades deep muscle (outer half of the detrusor muscle)[24]
- T3 Tumour invades perivesical tissue:
- T3a Microscopically
- T3b Macroscopically (extravesical mass)
- T4a Tumour invades prostate, uterus or vagina
- T4b Tumour invades pelvic wall or abdominal wall
N (Lymph nodes)
- NX Regional lymph nodes cannot be assessed
- N0 No regional lymph node metastasis
- N1 Metastasis in a single lymph node in true pelvis (hypogastric, obturator, external iliac, or presacral nodes)
- N2 Metastasis in multiple lymph nodes in true pelvis (hypogastric, obturator, external iliac, or presacral nodes)
- N3 Metastasis in common iliac lymph nodes
M (Distant metastasis)
- MX Distant metastasis cannot be assessed
- M0 No distant metastasis
- M1 Distant metastasis.
- M1a: The cancer has spread only to lymph nodes outside of the pelvis.
- M1b: The cancer has spread other parts of the body.
The most common sites for bladder cancer metastases are the lymph nodes, bones, lung, liver, and peritoneum.[25] The most common sentinel lymph nodes draining bladder cancer are obturator and internal iliac lymph nodes. The location of lymphatic spread depends on the location of the tumors. Tumors on the superolateral bladder wall spread to external iliac lymph nodes. Tumors on the neck, anterior wall and fundus spread commonly to the internal iliac lymph nodes.[26] From the regional lymph nodes (i.e. obturator, internal and external lymph nodes) the cancer spreads to distant sites like the common iliac lymph nodes and paraaortic lymph nodes.[27] Skipped lymph node lesions are not seen in bladder cancer.[26]
Numerical
The stages above can be integrated into a numerical staging (with Roman numerals) as follows:[28]
Stage | Tumor | Nodes | Metastasis | 5-year survival in the US[29] |
---|---|---|---|---|
Stage 0a | Ta | N0 | M0 | 98% |
Stage 0is | Tis | N0 | M0 | 95% |
Stage I | T1 | N0 | M0 | 63% |
Stage II | T2a | N0 | M0 | |
T2b | ||||
Stage IIIA | T3a | N0 | M0 | 35% |
T3b | ||||
T4a | ||||
T1-4a | N1 | |||
Stage IIIB | T1-4a | N2 | M0 | |
N3 | ||||
Stage IVA | T4b | Any N | M0 | |
Any T | M1a | |||
Stage IVB | Any T | Any N | M1b | 5% |
Grading
[edit]According to WHO classification (1973) bladder cancers are histologically graded into:[30]
- G1 – Well differentiated,
- G2 – Moderately differentiated
- G3 – Poorly differentiated
WHO classification (2004/2016)[31][32]
- Papillary lesions
- Urothelial Papilloma
- Papillary urothelial neoplasm of low malignant potential (PUNLMP)
- Low Grade
- High Grade
- Flat lesions
- Urothelial proliferation of uncertain malignant potential
- Reactive atypia
- Atypia of unknown significance
- Urothelial dysplasia
- Urothelial CIS (always high grade)
- Primary
- Secondary
- Concurrent
Risk stratification
[edit]People with non-muscle invasive bladder cancer (NMIBC), are risk-stratified based on clinical and pathological factors so that they are treated appropriately depending on their probability of having progression and/or recurrence.[33] People with non-muscle invasive tumors are categorized into low-risk, intermediate-risk and high-risk or provided with a numerical risk score. Risk-stratification framework is provided by American Urology Association/Society of Urological Oncology (AUA/SUO stratification), European Association of Urology (EAU) guidelines, European Organization for Research and Treatment of Cancer (EORTC) risk tables and Club Urológico Español de Tratamiento Oncológico (CUETO) scoring model.[34][35][36]
Low risk | Intermediate risk | High risk |
---|---|---|
Low grade solitary Ta tumor, smaller than 3 cm | Recurrence within 1 year, Low grade Ta tumor | High grade T1 |
Papillary urothelial neoplasm of low malignant potential | Solitary low grade Ta tumor, bigger than 3 cm | Any recurrent tumor or any high grade Ta |
Low grade Ta, multifocal tumors | High grade Ta, bigger than 3 cm (or multifocal) | |
High grade Ta, smaller than 3 cm | Any carcinoma in situ | |
Low grade T1 | Any BCG failure in high grade tumors | |
Any variant histology | ||
Any lymphovascular invasion | ||
Any high grade prostatic urethral involvement |
The EORTC and CUETO model use a cumulative score obtained from individual prognostic factors, which are then converted into risk of progression and recurrence. The six prognostic factors included in the EORTC model are number of tumors, recurrence rate, T-stage, presence of carcinoma-in-situ and grade of the tumor. Scoring for recurrence in the CUETO model incorporates 6 variables; age, gender, grade, tumor status, number of tumors and presence of tis. For progression scoring the previous 6 variables plus T stage is used.[36][37]
Model | Cumulative score for recurrence | Recurrence at 1-year (%) | Recurrence at 5-year (%) |
---|---|---|---|
EORTC | 0 | 15 | 31 |
1-4 | 24 | 46 | |
5-9 | 38 | 62 | |
10-17 | 61 | 78 | |
CUETO | 0-4 | 8.2 | 21 |
5-6 | 12 | 36 | |
7-9 | 25 | 48 | |
10-16 | 42 | 68 |
Model | Cumulative score for progression | Progression at 1-year (%) | Progression at 5-year (%) |
---|---|---|---|
EORTC | 0 | 0.2 | 0.8 |
2-6 | 1 | 6 | |
7-13 | 5 | 17 | |
12-23 | 17 | 45 | |
CUETO | 0-4 | 1.2 | 3.7 |
5-6 | 3 | 12 | |
7-9 | 5.5 | 21 | |
10-16 | 14 | 34 |
Treatment
[edit]![](http://upload.wikimedia.org/wikipedia/commons/thumb/2/28/Bladder_Cancer_Treatment_Guide_v4.png/310px-Bladder_Cancer_Treatment_Guide_v4.png)
The treatment of bladder cancer depends on how deeply the tumor invades into the bladder wall.[citation needed]
Treatment strategies for bladder cancer include:[40][41]
- Non-muscle invasive: transurethral resection of bladder tumor (TURBT) with or without intravesical chemotherapy or immunotherapy
- Muscle invasive
- Stage II/Stage IIIA: radical cystectomy plus neoadjuvant chemotherapy (multimodal therapy, preferred) or transurethral resection with chemoradiation (trimodal therapy, highly selected people) or partial cystectomy plus neoadjuvant chemotherapy (in highly selected people)
- Stage IIIB/IVA: cisplatin-based chemotherapy followed by radical cystectomy or chemoradiation or observation depending on treatment response
- Stage IVB (locally advanced; unresectable tumors): palliative radiotherapy
- Metastatic disease: cisplatin-based chemotherapy
- Metastatic disease but unfit for cisplatin-based chemotherapy: carboplatin-based chemotherapy
- Metastatic disease with contraindication for chemotherapy: checkpoint inhibitors if programmed death ligand 1 (PD L1) positive
- Squamous cell carcinoma or adenocarcinoma of bladder: radical cystectomy
Non-muscle invasive
[edit]Transurethral resection
[edit]Non-muscle invasive bladder cancer (those not entering the muscle layer of the bladder) can be "shaved off" using an electrocautery device attached to a cystoscope, which in that case is called a resectoscope. The procedure is called transurethral resection of bladder tumor (TURBT) and serves primarily for pathological staging. In case of non-muscle invasive bladder cancer the TURBT is in itself the treatment, but in case of muscle invasive cancer, the procedure is insufficient for final treatment.[42] Additionally, blue light cystoscopy with optical-imaging agent Hexaminolevulinate (HAL) is recommended at initial TURBT to increase lesion detection (especially carcinoma in situ) and improve resection quality thereby reducing recurrence.[43][44] It is important to assess the quality of the resection: if there is evidence of incomplete resection, or if there is no muscle in the specimen (without which muscle invasiveness cannot be determined), then a second TURBT is strongly recommended. Moreover, nearly half of the people with high-grade noninvasive disease have residual tumor after primary TURBT; in such cases a second TURBT is important for avoiding under-staging.[45][46] At this point classifying people into risk groups is recommended. Treatment and surveillance for different risk groups is indicated in the table below.[citation needed]
Another method for reducing recurrence of tumors is medication after TURBT surgery. The two most common medicines used for this purpose are Bacillus Calmette–Guérin (BCG) and mitomycin.[47] For people who have already had a TURBT procedure, BCG may lead to similar risk of death and may reduce the risk of tumor recurrence.[47] However, this medication may increase the risk of serious unwanted side effects.[47] More research is needed to confirm these results.
Chemotherapy
[edit]![](http://upload.wikimedia.org/wikipedia/commons/thumb/2/24/Diagram_showing_drug_treatment_into_the_bladder_CRUK_114.svg/220px-Diagram_showing_drug_treatment_into_the_bladder_CRUK_114.svg.png)
A single instillation of chemotherapy into the bladder after primary TURBT has shown benefit in deceasing recurrence by 35% in non-muscle invasive disease.[48] Medications which can be used for this purpose are mitomycin C (MMC), epirubicin, pirarubicin and gemcitabine. Instillation of post-operative chemotherapy should be conducted within first few hours after TURBT. As time progress residual tumor cells are known to adhere firmly and are covered by extracellular matrix which decrease the efficacy of the instillation.[46] The most common side effect is chemical cystitis and skin irritation.[48] If there is a suspicion of bladder perforation during TURBT, chemotherapy should not be instilled into the bladder as serious adverse events are known to occur due to drug extravasation. Studies have shown that efficacy of chemotherapy is increased by the use of Device assisted chemotherapy .[49] These technologies use different mechanisms to facilitate the absorption and action of a chemotherapy drug instilled directly into the bladder. Another technology – electromotive drug administration (EMDA) – uses an electric current to enhance drug absorption after surgical removal of the tumor.[50][51] Another technology, thermotherapy, uses radio-frequency energy to directly heat the bladder wall, which together with chemotherapy (chemohyperthermia) shows a synergistic effect, enhancing each other's capacity to kill tumor cells.[52]
Immunotherapy
[edit]![](http://upload.wikimedia.org/wikipedia/commons/thumb/2/25/Mycobacterium_bovis_BCG_ZN.jpg/220px-Mycobacterium_bovis_BCG_ZN.jpg)
Immunotherapy by Bacillus Calmette–Guérin (BCG) delivery into the bladder is also used to treat and prevent the recurrence of NMIBC.[53] BCG is a vaccine against tuberculosis that is prepared from attenuated (weakened) live bovine tuberculosis bacillus, Mycobacterium bovis, that has lost its virulence in humans. BCG immunotherapy is effective in up to 2/3 of the cases at this stage, and in randomized trials has been shown to be superior to standard chemotherapy.[54] The exact mechanism by which BCG prevents recurrence is unknown. However, it has been shown that the bacteria are taken up by the cancer cells.[55] The infection of these cells in the bladder may trigger a localized immune reaction which clears residual cancer cells.[56][57]
BCG is delivered as induction and a maintenance course. The induction course consists of 6-week course of intravesical and percutaneous BCG.[58] This is followed by a maintenance course. There is no consensus regarding the maintenance schedule, however the most commonly followed is the Southwestern Oncology Group (SWOG) schedule.[59] The SWOG maintenance schedule consists of intravesical and percutaneous BCG every week for 3 weeks given at 3, 6, 12, 18, 24, 30 and 36 months.[58] Three weekly maintenance regimen with induction has shown complete response rate of 84% compared to 69% in people who received 6-week induction BCG only at 6 months. Many studies have explored alternate treatment schedules and regimes of BCG but has shown no clinical significance.[58] Efficacy of different strains of BCG (Connaught, TICE, Pasteur, Tokio-172) has been shown not to be different however, there is no high-level evidence.[60]
Side effects of BCG therapy include cystitis, prostatitis, epididymo-orchitis, balanitis, ureteral obstruction, bladder contraction, mycobacterial osteomyelitis, reactive arthritis, mycobacterial pneumonia, granulomatous hepatitis, granulomatous nephritis, interstitial nephritis, infectious vasculitis and disseminated infection.[61][62]
Local infection (i.e. prostatitis, epididymo-orchitis, balanitis) because of BCG should be treated with triple tubercular therapy, with one of the drug being fluoroquinolone for 3 to 6 months. In people with systemic infections, BCG therapy should be stopped and anti-tubercular multidrug treatment for at-least 6 months should be started. Medications that can be used for this treatment are INH, rifampicin, ethambutol, fluoroquinolones, clarithromycin, aminoglycosides, and doxycycline. BCG strains are not sensitive to pyrazinamide therefore, it should not be a part of anti-tubercular treatment.[63]
Nogapendekin alfa inbakicept (Anktiva), used in combination with Bacillus Calmette-Guérin was approved for medical use in the United States in April 2024.[64]
BCG treatment failure
[edit]BCG treatment failure can be classified into 3 groups; BCG relapse, BCG-refractory and BCG-intolerant. In BCG relapse, tumor reoccurs after a disease free period. BCG-refractory tumors are the ones which do not respond to induction and maintenance doses of BCG or which progress during therapy. In BCG-intolerant, tumor reoccurs due to incomplete treatment as the person receiving it is unable to tolerate an induction course of BCG. Around 50% of the people fail BCG treatment and would require further treatment.[58]
People whose tumors recurred after treatment with BCG or who were unresponsive to treatment, are more difficult to treat.[65] In such people a radical cystectomy is recommendation[66][67] In people who do not show response to BCG therapy and are unfit or unwilling to undergo radical cystectomy, salvage therapies can be considered. Salvage therapy include intravesical chemotherapy with agents such as valrubicin, gemcitabine or docetaxel, chemoradiation or chemohyperthermia.[68]
Risk | Other considerations | Chemotherapy | Immunotherapy (BCG) | Cystoscopy (surveillance) | Imaging (surveillance) |
---|---|---|---|---|---|
Low | at 3-months followed by cystoscopy at 12-months, then yearly for 5-years | CT/MR urography and CT/MRI of abdomen and pelvis at baseline | |||
Intermediate | Primary tumor with history of chemotherapy | Intravesical chemotherapy for 1 year OR Intravesical BCG for 1 year (preferred) | at 3-months with cytology followed by once every 3–6 months for 5-years and then yearly | CT/MR urography and CT/MRI of abdomen and pelvis at baseline | |
Recurrent tumors with history of previous chemotherapy | Intravesical BCG for 1 year | ||||
High | Intravesical BCG for 3 year (as tolerated) | at 3-months with cytology followed by once every 3-months for 2-years after that, 6 monthly for 5 years then yearly | CT/MR urography and CT/MRI of abdomen and pelvis at baseline, CT/MR urography 1-2 yearly for 10 years | ||
T1G3/High grade, Lymphovascular invasion, Presence of variant histology | Consider radical cystectomy |
Photodynamic Therapy
[edit]Photodynamic therapy (PDT) is a treatment option involving the administration of a photosensitizing agent, followed by the exposure of the bladder’s inner lining to a specific wavelength of light through a cystoscope. The light activation of the photosensitizer helps to destroy cancerous cells while sparing much of the surrounding healthy tissue.[69][70]
PDT is particularly advantageous for patients who might be at high risk from surgery or those who prefer a less invasive option. The procedure is known for its precision and the ability to be repeated, which is important for managing the recurrent nature of NMIBC. Clinical trials and studies have shown that PDT can be effective in reducing tumor recurrence rates and is associated with a favorable safety profile, emphasizing its potential as a primary or adjuvant treatment modality.[71]
Research continues to evaluate the long-term outcomes of PDT for bladder cancer and explore potential improvements in photosensitizers and light delivery systems to enhance the treatment’s efficacy and patient outcomes.[72]
Muscle invasive
[edit]![](http://upload.wikimedia.org/wikipedia/commons/thumb/a/ac/Diagram_showing_bladder_reconstruction_CRUK_111.svg/220px-Diagram_showing_bladder_reconstruction_CRUK_111.svg.png)
Multimodal therapy (standard treatment)
[edit]Untreated, non-muscle invasive tumors may gradually begin to infiltrate the muscular wall of the bladder (muscle invasive bladder cancer). Tumors that infiltrate the bladder wall require more radical surgery, where part (partial cystectomy) or all (radical cystectomy) of the bladder is removed (a cystectomy) and the urinary stream is diverted into an isolated bowel loop (called an ileal conduit or urostomy). In some cases, skilled surgeons can create a substitute bladder (a neobladder) from a segment of intestinal tissue, but this largely depends upon a person's preference, age of the person, renal function, and the site of the disease.[citation needed]
A bilateral pelvic lymphadenectomy should accompany radical cystectomy. At minimum, a standard template of lymphadenectomy should be followed by removing the external and internal iliac and obturator lymph node.[73] When performing a lymphadenectomy, the surgeon can either remove lymph nodes from a smaller (standard) or from larger (extended) area. In comparison with a standard lymph node dissection, having an extended dissection may reduce a person's likelihood of death from any reason, including dying from bladder cancer.[74] The extended procedure may lead to more serious unwanted effects and may or may not influence the likelihood of the cancer recurring over time.[74] The rate of not-so-serious side effects may be similar for both surgeries.[74]
Radical cystectomy has a significant morbidity associated with it. About 50-65% of the people experience complication within 90 days of surgery.[75][76] Mortality rates was 7% within 90 days of surgery. High volume centers have better outcomes than low volume centers.[77] Some centers are implementing Enhanced Recovery After Surgery (ERAS) society recommendations to decrease morbidity after radical cystectomy. However, due to lack of specific evidence in urologic surgery, ERAS protocol has not been widely incorporated in urologic clinical care.[78]
Even after surgical removal of bladder, 50% of the people with muscle invasive disease (T2-T4) develop metastatic disease within two years due to micrometastasis.[79] In such, neoadjuvant chemotherapy (chemotherapy before main treatment, i.e. surgery) has shown to increase overall survival at 5 years from 45% to 50% with an absolute survival benefit of 5%.[80][81][82] Currently the two most used chemotherapy regimens for neoadjuvant chemotherapy are platinum based; methotrexate, vinblastine, doxorubicin, cisplatin (MVAC) and gemcitabine with cisplatin (GC).[83] Other regimens include dose dense MVAC (DDMVC) and cisplatin, methotrexate and vinblastine (CMV). Although, the optimal regimen has not been established, the preferred regimen for neoadjuvant therapy is MVAC.[83]
Role of adjuvant chemotherapy (chemotherapy after main treatment) is limited to people with high grade tumours (pT3/T4and/or N+) and who have not been treated with neoadjuvant therapy.[73] Adjuvant radiation therapy has not shown any advantage in bladder cancer treatment.[84]
MVAC | DDMVAC | Gemcitabine + cisplatin |
---|---|---|
Methotrexate (30 mg/m2 IV) - day 1,15,22
Vinblastine (3 mg/m2 IV) - day 2, 15, 22 Doxorubicin (30 mg/m2 IV) - day 2 Cisplatin (70 mg/m2 IV) - day 2 Repeat every 4 weeks for 3 cycles |
Methotrexate (30 mg/m2 IV) - day 1 Vinblastine (3 mg/m2 IV) - day 2 Doxorubicin (30 mg/m2 IV) - day 2 Cisplatin (70 mg/m2 IV) - day 2 Granulocyte colony-stimulating factor (G-CSF) (240μg/m2 SC) - day 4-10 Repeat every 2 weeks for 3–4 cycles |
Gemcitabine (1,000 mg/m2 IV) - day 1,8,15 Cisplatin (70 mg/m2) - day 2 Repeat every 4 weeks for 4 cycles |
Trimodal therapy (alternative treatment)
[edit]A combination of radiation and chemotherapy (chemoradiation) in conjunction with transurethral (endoscopic) bladder tumor resection can be used as an alternative in certain people.[87] Review of available large data series on this so-called trimodality therapy has indicated similar long-term cancer specific survival rates, with improved overall quality of life as for people undergoing radical cystectomy with urinary reconstruction. However, currently no randomized control trials are available which has compared trimodal therapy with radical cystectomy. People who undergo trimodal therapy are usually highly selected and generally have T2 disease without hydronephrosis and/or carcinoma in-situ.[88] Five year cancer specific survival and overall survival after trimodal therapy is between 50% to 82% and 36% to 74%.[87]
In trimodal therapy, a maximal TURBT is conducted followed by chemoradiation therapy. Radiation sensitizing chemotherapy regimens consisting of cisplatin or 5-flurouracil and mitomycin C are used. Radiation therapy is via external bean radiotherapy (EBRT) with a target curative dose of 64-66 Gy.[89] Surveillance for progression or recurrence should conducted with the aid of CT scans, cystoscopies and urine cytology.[73] Side effects of chemoradiation include nausea, vomiting, loss of appetite, hair loss, mouth sores, diarrhea, constipation, increased risk of infections and bleeding and fatigue.[90]
In people who fail trimodal therapy, radical cystectomy is considered if there is muscle invasive or recurrent tumors. Around 25-30% fail treatment and undergo salvage radical cystectomy.[87] TURBT with intravesical therapy is indicated after treatment failure for non-muscle invasive disease.[73]
Partial cystectomy
[edit]In people with solitary tumor without concurrent carcinoma in situ in an area where a clean surgical margins can be achieved, a partial cystectomy with lymphadenectomy can be considered. Management plan including partial cystectomy should be accompanied with neoadjuvant chemotherapy.[41] In people with urachal adenocarcinoma of the bladder, a partial cystectomy with en-bloc resection of urachal ligament and umbilicus can be considered.[91]
Metastatic disease
[edit]First line treatment
[edit]Cisplatin-containing combination chemotherapy is the standard of care for metastatic bladder care.[92] Fitness for receiving cisplatin based chemotherapy is assessed before treatment. A person is deemed unfit if anyone of the following is true.[93]
- Eastern Cooperative Oncology Group performance status of 2
- Creatinine clearance < 60 mL/min
- Grade ≥ 2 hearing loss
- Grade ≥ 2 neuropathy
- New York Heart Association Class III heart failure
People who are deemed fit receive platinum based regimens; methotrexate, vinblastine, doxorubicin, with cisplatin (MVAC) or gemcitabine with cisplatin (GC). Alternative regimens include paclitaxel with gemcitabine and cisplatin (PCG, triple therapy) and cisplatin, methotrexate and vinblastine (CMV). Response rate for cisplatin-based combination ranges from 39 to 65% and complete response is seen in 12-35% of the people.[94] MVAC is better tolerated if it is combined with granulocyte colony-stimulating factor and the regimen is known as dose dense MVAC regimen (DDMVAC). This combination has shown to decease all cause mortality.[95] MVAC regimen is aggressive. Febrile neutropenia (fever due to decrease in white blood cells) occurs in 10 to 14% and death due to toxicity in about 3-4%. Common side effects of MVAC include suppression of bone marrow, fever due to decrease in white blood cells, sepsis, mucositis, and nausea and vomiting.[94] In contrast, the GC regimen has shown lower rates of neutropenic sepsis and grade 3/4 mucositis compared to MVAC.[96] Efforts have been made to increase tolerance of cisplatin-based regimen by replacing it with carboplatin-based chemotherapy. However, cisplatin-based therapy is superior to carboplatin-based chemotherapy in achieving overall and complete response.[97] Nevertheless, nearly half of the people with metastatic disease are "unfit" for cisplatin-based therapy. In such persons a combination of carboplatin and gemcitabine (GemCarbo) can be used as first line chemotherapy.[98] In people who are not eligible for any platinum based chemotherapy and have PD-L1 expression, Atezolizumab and Pembrolizumab can be used.[citation needed]
People with bone metastasis should receive bisphosphonates or denosumab to prevent skeletal related events (e.g. fractures, spinal cord compression, bone pain).[99]
DDMVAC | Gemcitabine + Cisplatin |
---|---|
Methotrexate (30 mg/m2 IV) - day 1
Vinblastine (3 mg/m2 IV) - day 2 Doxorubicin (30 mg/m2 IV) - day 2 Cisplatin (70 mg/m2 IV) - day 2 Granulocyte colony-stimulating factor (G-CSF) (240μg/m2 SC) - day 4-10 Repeat every 2 weeks for 3–4 cycles |
Gemcitabine (1,000 mg/m2 IV) - day 1,8,15 Cisplatin (70 mg/m2) - day 2 Repeat every 4 weeks for 4 cycles |
Atezolizumab (in PD-L1+) | Gemcitabine + Carboplatin | Pembrolizumab (in PD-L1+) |
---|---|---|
Atezolizumab (Atezolizumab 1200 mg IV)
every 3 weeks |
Gemcitabine (1,000 mg/m2 IV) - day 1,8 Carboplatin (4.5 × [glomerular filtration rate + 25]) - day 1 and every 3 weeks |
Pembrolizumab 200 mg every 3 weeks |
Second line treatment
[edit]Bladder cancer that is refractory or shows progression after platinum-based chemotherapy can be treated with second-line chemotherapy or immunotherapy.[citation needed]
The most commonly used second-line chemotherapy is single-agent regimes of Taxanes (Paclitaxel, nab-paclitaxel and Docetaxel). Other single-agent regimes include Vinflunine, a third generation vinca alkaloid (approved in Europe), Gemcitabine, Pemetrexed, Oxaliplatin, and Ifosfamide.[100][101][102] Side effects of Vinflunine include neutropenia, constipation, fatigue and anemia and has limited its use as a second line agent. Response to second-line chemotherapy occurs in 5%–20% people. Median progression free survival with second-line chemotherapy is 3–4 months.[103]
In people with fibroblast growth factor receptors (FGFR) mutations and fail standard platinum based chemotherapy erdafitinib can be used. Erdafitinib has shown a response rate of 40% in these patients.[104]
Five immunotherapy agents have been approved in the US for use in metastatic bladder cancer. They act by inhibiting programmed cell-death protein 1 (PD-1) or programmed cell-death ligand 1 (PD-L1). Pembrolizumab and nivolumab, and are inhibitors of programmed cell-death ligand 1 (PD-1). Avelumab, atezolizumab and durvalumab are inhibitors of PD-L1.[105][106]
Pembrolizumab probably improves overall survival a little and may slightly improve quality of life for people with urothelial cancer that has worsened after initial treatment when compared with continued chemotherapy.[107] However, pembrolizumab may have only minimal effects on the rate of death resulting from treatment or the rate at which the cancer advances.[107] Pembrolizumab may cause less serious side effects than chemotherapy.[107]
Atezolizumab | Nivolumab | Pembrolizumab | Durvalumab | Avelumab |
---|---|---|---|---|
Atezolizumab 1200 mg IV
every 3 weeks |
Nivolumab 3 mg/kg IV every 2 weeks |
Pembrolizumab 200 mg every 3 weeks |
Durvalumab 10 mg/kg every 2 weeks for 12 months |
Avelumab 10 mg/kg IV every 2 weeks |
Surveillance and response
[edit]Contrast enhanced CT is used to monitor lung, liver, and lymph node metastases. A bone scan is used to detect and monitor bone metastasis.[108] Treatment response is measured using the Response evaluation criteria in solid tumors (RECIST) into one of the following groups; response (complete or partial), stable disease and progressive disease.[109]
Causes
[edit]Bladder cancer is caused by genetic damage to the DNA of bladder cells. These changes can be random, or can be induced by exposure of the bladder to toxic substances such as those from consuming tobacco. The accumulation of this genetic damage disrupts the normal functioning of bladder cells, causing them to grow uncontrollably and form a tumor.[110]
Smoking
[edit]Tobacco smoking is the main known contributor to urinary bladder cancer; in most populations, smoking is associated with over half of bladder cancer cases in men and one-third of cases among women,[111] however these proportions have reduced over recent years since there are fewer smokers in Europe and North America.[112] There is an almost linear relationship between smoking duration (in years), pack years and bladder cancer risk. A risk plateau at smoking about 15 cigarettes a day can be observed (meaning that those who smoke 15 cigarettes a day are approximately at the same risk as those smoking 30 cigarettes a day). Smoking in any form (cigar, cigarette, pipe, Egyptian waterpipe and smokeless tobacco) increases the risk for bladder cancer.[113] Quitting smoking reduces the risk. Risk of bladder cancer decreases by 30% within 1–4 years and continues to decrease by 60% at 25 years after smoking cessation.[114] However, former smokers will most likely always be at a higher risk of bladder cancer compared to people who have never smoked.[112] Passive smoking also appears to be a risk.[115][116]
Opium consumption increases the risk of bladder cancer threefold, while concurrent use of opium and tobacco increases the risk of bladder cancer fivefold when compared to the general population.[117]
Occupational exposure
[edit]Thirty percent of bladder tumors probably result from occupational exposure in the workplace to carcinogens. Occupational or circumstantial exposure to the following substances has been implicated as a cause of bladder cancer; benzidine (dyes manufacturing), 4-aminobiphenyl (rubber industry), 2-naphtylamine (azo dyes manufacturing, foundry fumes, rubber industry, cigarette smoke and cancer research), phenacetin (analgesic), arsenic and chlorinated aliphatic hydrocarbons in drinking water, auramine (dye manufacturing), magenta (dye manufacturing), ortho-toluidine (dye manufacturing), epoxy and polyurethane resin hardening agents (plastics industry), chlornaphazine, coal-tar pitch.[118][119][120][121][122] Occupations at risk are bus drivers, rubber workers, painters, motor mechanics, leather (including shoe) workers, blacksmiths, machine setters, and mechanics.[123][124] Hairdressers are thought to be at risk as well because of their frequent exposure to permanent hair dyes.[125]
Infection
[edit]Infection with Schistosoma haematobium (bilharzia or schistosomiasis) may cause bladder cancer, particularly of the squamous cell type.[126] Schistosoma eggs induces a chronic inflammatory state in the bladder wall resulting in tissue fibrosis.[127] Higher levels of N-nitroso compounds has been detected in urine samples of people with schistosomiasis.[128] N-Nitroso compounds have been implicated in the pathogenesis of schistosomiasis related bladder cancer. They cause alkylation DNA damage, specially Guanine to Adenine transition mutations in the HRAS and p53 tumor suppressor gene.[129] Mutations of p53 are detected in 73% of the tumors, BCL-2 mutations accounting for 32% and the combination of the two accounting for 13%.[130] Other causes of squamous cell carcinoma of the bladder include chronic catheterizations in people with a spinal cord injury and history of treatment with cyclophosphamide.[131][132]
Diet
[edit]The American Institute for Cancer Research have stated that there is strong evidence that drinking water containing arsenic increases the risk of bladder cancer.[133]
High consumption of animal fat and dietary cholesterol increases bladder cancer risk in men.[134]
Ingestion of aristolochic acid present in many Chinese herbal medications has been shown to cause urothelial carcinoma and kidney failure.[135] Aristolochic acid activates peroxidase in the urothelium and causes transversion mutation in the TP53 tumor suppressor gene.[citation needed]
Other
[edit]People who undergo external beam radiotherapy (EBRT) for prostate cancer have a higher risk of developing invasive bladder cancer.[136]
In addition to these major risk factors there are also numerous other modifiable factors that are less strongly (i.e. 10–20% risk increase) associated with bladder cancer, for example, obesity.[137] Although these could be considered as minor effects, risk reduction in the general population could still be achieved by reducing the prevalence of a number of smaller risk factor together.[138]
Genetics
[edit]Mutations in FGFR3, TP53, PIK3CA, KDM6A, ARID1A, KMT2D, HRAS, TERT, KRAS, CREBBP, RB1 and TSC1 genes may be associated with some cases of bladder cancer.[139][140][141] Deletions of parts or whole of chromosome 9 is common in bladder cancer.[142] Low grade cancer are known to harbor mutations in RAS pathway and the fibroblast growth factor receptor 3 (FGFR3) gene, both of which play a role in the MAPK/ERK pathway. p53 and RB gene mutations are implicated in high-grade muscle invasive tumors.[143] Eighty nine percent of muscle invasive cancers have mutations in chromatin remodeling and histone modifying genes.[144] Deletion of both copies of the GSTM1 gene has a modest increase in risk of bladder cancer. GSTM1 gene product glutathione S-transferase M1 (GSTM1) participates in the detoxification process of carcinogens such as polycyclic aromatic hydrocarbons found in cigarette smoke.[145] Similarly, mutations in NAT2 (N-acetyltransferase) is associated with increased risk for bladder cancer. N-acetyltransferase helps in detoxification of carcinogens like aromatic amines (also present in cigarette smoke).[146] Various single-nucleotide polymorphisms in PSCA gene present on chromosome 8 have shown to increase the risk for bladder cancer. PSCA gene promoter region has an androgen response region. Loss of reactivity of this region to androgens is hypothesized as a cause of more aggressive tumors in women (unlike in men who have higher amount of androgen).[147]
Muscle invasive bladder cancer are heterogeneous in nature. In general, they can be genetically classified into basal and luminal subtypes. Basal subtype show alterations involving RB and NFE2L2 and luminal type show changes in FGFR3 and KDM6A genes.[148] Basal subtype are subdivided into basal and claudin low-type group and are aggressive and show metastasis at presentation, however they respond to platinum based chemotherapy. Luminal subtype can be subdivided into p53-like and luminal. p53-like tumors of luminal subtype although not as aggressive as basal type, show resistance to chemotherapy[149]
Prevention
[edit]Diet
[edit]As of 2019, there is limited high level evidence to suggest that eating vegetable and fruits decreases the risk of bladder cancer.[146] Fruit and yellow-orange vegetables, particularly carrots and those containing selenium, citrus fruits and cruciferous vegetables have been identified as having a possibly protective effect.
While it is suggested that the polyphenol compounds in tea may have an inhibitory effect on bladder tumor formation and growth, there is limited evidence to suggesting drinking tea decreases bladder cancer risk.[146] A 2022 review found that a Mediterranean diet has a protective effect on bladder cancer risk.[150] Higher consumption of monounsaturated fat and plant-based oils decrease bladder cancer risk in women.[134] Higher consumption of total dietary fiber and whole grains is associated with a reduced risk of bladder cancer.[151]
Screening
[edit]As of 2019 there is insufficient evidence to determine if screening for bladder cancer in people without symptoms is effective or not.[152]
Prognosis
[edit]People with non-muscle invasive tumors have a favorable outcome (5-year survival is 95% vs. 69% of muscle invasive bladder cancer).[153][154] However, 70% of them will have a recurrence after initial treatment with 30% of them presenting with muscle invasive disease.[155] Recurrence and progression to a higher disease stage have a less favorable outcome.[156]
Survival after radical cystectomy and pelvic lymph node dissection is dependent on the pathological stage. If the disease has not spread to the lymph node and is limited to the bladder (T1 or T2, N0) the 5-year survival is 78%. If it has spread locally around the region of the bladder with no lymph node involved (T3, N0) then the 5-year survival drops to 47%. In disease with lymph node spread (N+, irrespective of T stage) the 5-year survival is 31%. Locally advanced and metastatic disease drastically decreases survival, with a median survival of 3–6 months without chemotherapy. Cisplatin-based chemotherapy has increased the median survival to 15-months. However, the 5-year survival is still 15%.[157]
There are several prognostic factors which determine cancer specific survival after radical cystectomy. Factor with detrimental effect of cancer specific survival are old age, higher tumor grade and pathological stage, lymph node metastasis, presence of lymphovascular invasion and positive soft tissue margin.[158] Lymph node density (positive lymph nodes/total lymph nodes observed in the specimen from surgery) is a predictor of survival in lymph node positive disease. Higher the density lower is the survival.[159]
Quality of life
[edit]After radical cystectomy, urinary and sexual function remain inferior to the general population. People who have a neobladder have better emotional function and body image compared with ones with cutaneous diversion (who need to wear a bag to collect urine over their abdomen).[160] Social factors such as family, relationships, health and finances contribute significantly for determining good quality of life in people who have been diagnosed with bladder cancer.[161]
A high percentage of people with bladder cancer have anxiety and depression.[162] People who are young, single and have advanced clinical disease have a high risk for getting diagnosed with a psychiatric illness post-treatment. People with psychiatric illness post treatment seem to have worse cancer specific and overall survival.[163][164]
Epidemiology
[edit]Rank | Country | Overall | Men | Women |
---|---|---|---|---|
1 | Lebanon | 25 | 40 | 9 |
2 | Greece | 21 | 40 | 4 |
3 | Denmark | 18 | 29 | 8 |
4 | Hungary | 17 | 27 | 9 |
5 | Albania | 16 | 27 | 6 |
5 | Netherlands | 16 | 26 | 8 |
7 | Belgium | 16 | 27 | 6 |
8 | Italy | 15 | 27 | 6 |
9 | Germany | 15 | 26 | 6 |
10 | Spain | 15 | 27 | 6 |
![](http://upload.wikimedia.org/wikipedia/commons/thumb/c/ce/Bladder_cancer_world_map_-_Death_-_WHO2004.svg/340px-Bladder_cancer_world_map_-_Death_-_WHO2004.svg.png)
Around 500,000 people are diagnosed with bladder cancer each year, and 200,000 die of the disease.[168] This makes bladder cancer the tenth most commonly diagnosed cancer, and the thirteenth cause of cancer deaths.[169] Bladder cancer is most common in wealthier regions of the world, where exposure to certain carcinogens is highest. It is also common in places where schistosome infection is common, such as North Africa.[169]
Bladder cancer is much more common in men than women; around 1.1% of men and 0.27% of women develop bladder cancer.[11] This makes bladder cancer the sixth most common cancer in men, and the seventeenth in women.[170] When women are diagnosed with bladder cancer, they tend to have more advanced disease and consequently a poorer prognosis.[170] This difference in outcomes is attributed to numerous factors such as, difference in carcinogen exposure, genetics, social and quality of care.[147] One of the common signs of bladder cancer is hematuria and is quite often misdiagnosed as urinary tract infection in women, leading to a delay in diagnosis.[147] Smoking can only partially explain this higher rates in men in western hemisphere.[171] In Africa, men are more prone to do field work and are exposed to infection with Schistosoma, this may explain to a certain extent the gap in incidence of squamous cell cancers in areas where bladder cancer is endemic.[171]
As with most cancers, bladder cancer is more common in older people; the average person with bladder cancer is diagnosed at age 73.[172]
Veterinary medicine
[edit]References
[edit]- ^ a b c d e f g h i j k l m n "Bladder Cancer Treatment (PDQ®)–Patient Version - National Cancer Institute". www.cancer.gov. 11 May 2020. Retrieved 4 June 2020.
- ^ a b c d e "Cancer of the Urinary Bladder - Cancer Stat Facts". SEER. Retrieved 30 October 2019.
- ^ a b c d e "Bladder Cancer Factsheet" (PDF). Global Cancer Observatory. Retrieved 8 November 2019.
- ^ Heyes S.M., Prior K.N., Whitehead D., Bond M.J. Toward an Understanding of Patients' and Their Partners' Experiences of Bladder Cancer. Cancer Nurs.. 2020;43(5):E254-E263. doi:10.1097/NCC.0000000000000718
- ^ "Bladder Cancer Treatment". National Cancer Institute. 5 June 2017. Archived from the original on 14 July 2017. Retrieved 18 July 2017.
- ^ "EAU Guidelines: Non-muscle-invasive Bladder Cancer". Uroweb.
- ^ "Bladder Cancer - Stages and Grades". Cancer.Net. 25 June 2012.
- ^ "Bladder cancer". World Cancer Research Fund. 24 April 2018.
- ^ "Survival statistics for bladder cancer - Canadian Cancer Society". www.cancer.ca.
- ^ a b c Dyrskjøt et al. 2023, "Clinical Presentation".
- ^ a b c Lenis, Lec & Chamie 2020, p. 1981.
- ^ a b Hahn 2022, "Clinical Presentation and Diagnostic Workup".
- ^ Abeloff's clinical oncology. Niederhuber, John E.,, Armitage, James O., 1946-, Doroshow, James H.,, Kastan, M. B. (Michael B.),, Tepper, Joel E.,, Preceded by: Abeloff, Martin D. (6th ed.). Philadelphia, PA. 8 January 2019. p. 1388. ISBN 978-0-323-56815-9. OCLC 1089396489.
{{cite book}}
: CS1 maint: location missing publisher (link) CS1 maint: others (link) - ^ a b c d e "Tests for Bladder Cancer". American Cancer Society. 12 March 2024. Retrieved 8 August 2024.
- ^ Dyrskjøt et al. 2023, "Diagnosis and Screening".
- ^ a b Ahmadi, Duddalwar & Daneshmand 2021, "Urine Cytology and Other Urine-Based Tumor Markers.
- ^ a b Ahmadi, Duddalwar & Daneshmand 2021, pp. 532–533.
- ^ Lenis, Lec & Chamie 2020, p. 1982.
- ^ a b Dyrskjøt et al. 2023, "Tissue-Based Diagnosis of Bladder Cancer".
- ^ a b c d "Types of Bladder Cancer". Cancer Research UK. 22 September 2024. Retrieved 26 August 2024.
- ^ Awiwi, MO; Vikram, R (18 June 2022). "Radiologic Diagnosis and Staging of Bladder Cancer: An Update". Journal of Computer Assisted Tomography. 46 (4): 530–544. doi:10.1097/RCT.0000000000001322. PMID 35723651. S2CID 249869037. Retrieved 23 June 2022.
- ^ "EAU Guidelines - STAGING AND CLASSIFICATION SYSTEMS". Uroweb.
- ^ Magers MJ, Lopez-Beltran A, Montironi R, Williamson SR, Kaimakliotis HZ, Cheng L (January 2019). "Staging of bladder cancer". Histopathology. 74 (1): 112–134. doi:10.1111/his.13734. PMID 30565300.
- ^ a b "Bladder Cancer: Stages and Grades". Cancer.net. 25 June 2012. Approved by the Cancer.Net Editorial Board 05/2019
- ^ Shinagare AB, Ramaiya NH, Jagannathan JP, Fennessy FM, Taplin ME, Van den Abbeele AD (January 2011). "Metastatic pattern of bladder cancer: correlation with the characteristics of the primary tumor". AJR. American Journal of Roentgenology. 196 (1): 117–22. doi:10.2214/AJR.10.5036. PMID 21178055.
- ^ a b Mao Y, Hedgire S, Prapruttam D, Harisinghani M (16 September 2014). "Imaging of Pelvic Lymph Nodes". Current Radiology Reports. 2 (11). doi:10.1007/s40134-014-0070-z.
- ^ Shankar PR, Barkmeier D, Hadjiiski L, Cohan RH (October 2018). "A pictorial review of bladder cancer nodal metastases". Translational Andrology and Urology. 7 (5): 804–813. doi:10.21037/tau.2018.08.25. PMC 6212631. PMID 30456183.
- ^ "How is bladder cancer staged?". American Cancer Society. Archived from the original on 4 October 2015. Last Medical Review: 11/02/2019
- ^ "Survival rates for bladder cancer by stage". American Cancer Society. Archived from the original on 13 October 2015. Last Medical Review: 02/26/2014
- ^ Seth P. Lerner. "Overview of Diagnosis and Management of Non-Muscle Invasive Bladder Cancer" (PDF). Food and Drug Administration. ODAC 14 September 2016
- ^ Epstein JI, Amin MB, Reuter VR, Mostofi FK (December 1998). "The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee". The American Journal of Surgical Pathology. 22 (12): 1435–48. doi:10.1097/00000478-199812000-00001. PMID 9850170.
- ^ Compérat EM, Burger M, Gontero P, Mostafid AH, Palou J, Rouprêt M, et al. (May 2019). "Grading of Urothelial Carcinoma and The New "World Health Organisation Classification of Tumours of the Urinary System and Male Genital Organs 2016"". European Urology Focus. 5 (3): 457–466. doi:10.1016/j.euf.2018.01.003. PMID 29366854.
- ^ a b Chang SS, Boorjian SA, Chou R, Clark PE, Daneshmand S, Konety BR, et al. (October 2016). "Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline". The Journal of Urology. 196 (4): 1021–9. doi:10.1016/j.juro.2016.06.049. PMID 27317986.
- ^ a b "Bladder Cancer: Non-Muscle Invasive Guideline - American Urological Association". www.auanet.org. Archived from the original on 7 August 2020. Retrieved 30 October 2019.
- ^ Soukup V, Čapoun O, Cohen D, Hernández V, Burger M, Compérat E, et al. (November 2018). "Risk Stratification Tools and Prognostic Models in Non-muscle-invasive Bladder Cancer: A Critical Assessment from the European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel". European Urology Focus. 6 (3): 479–489. doi:10.1016/j.euf.2018.11.005. PMID 30470647. S2CID 53722156.
- ^ a b Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, et al. (March 2006). "Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials". European Urology. 49 (3): 466–5, discussion 475–7. doi:10.1016/j.eururo.2005.12.031. PMID 16442208.
- ^ Fernandez-Gomez J, Madero R, Solsona E, Unda M, Martinez-Piñeiro L, Gonzalez M, et al. (November 2009). "Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model". The Journal of Urology. 182 (5): 2195–203. doi:10.1016/j.juro.2009.07.016. PMID 19758621.
- ^ "EAU Guidelines: Non-muscle-invasive Bladder Cancer". Uroweb.
- ^ Choi SY, Ryu JH, Chang IH, Kim TH, Myung SC, Moon YT, et al. (October 2014). "Predicting recurrence and progression of non-muscle-invasive bladder cancer in Korean patients: a comparison of the EORTC and CUETO models". Korean Journal of Urology. 55 (10): 643–9. doi:10.4111/kju.2014.55.10.643. PMC 4198762. PMID 25324946.
- ^ Kamat AM, Hahn NM, Efstathiou JA, Lerner SP, Malmström PU, Choi W, et al. (December 2016). "Bladder cancer". Lancet. 388 (10061): 2796–2810. doi:10.1016/S0140-6736(16)30512-8. PMID 27345655. S2CID 29104789.
- ^ a b c "NCCN Bladder cancer guidelines 2018" (PDF). Retrieved 25 November 2019.
- ^ a b "Uroweb - European Association of Urology (EAU)". Uroweb. Retrieved 7 November 2019.
- ^ Witjes JA, Babjuk M, Gontero P, Jacqmin D, Karl A, Kruck S, et al. (November 2014). "Clinical and cost effectiveness of hexaminolevulinate-guided blue-light cystoscopy: evidence review and updated expert recommendations" (PDF). European Urology. 66 (5): 863–71. doi:10.1016/j.eururo.2014.06.037. PMID 25001887.
- ^ Daneshmand S, Schuckman AK, Bochner BH, Cookson MS, Downs TM, Gomella LG, et al. (October 2014). "Hexaminolevulinate blue-light cystoscopy in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on appropriate use in the USA". Nature Reviews. Urology. 11 (10): 589–96. doi:10.1038/nrurol.2014.245. PMID 25245244.
- ^ Miladi M, Peyromaure M, Zerbib M, Saïghi D, Debré B (March 2003). "The value of a second transurethral resection in evaluating patients with bladder tumours". European Urology. 43 (3): 241–5. doi:10.1016/s0302-2838(03)00040-x. PMID 12600426. S2CID 5784606.
- ^ a b "EAU Guidelines: Non-muscle-invasive Bladder Cancer". Uroweb.
- ^ a b c Schmidt, Stefanie; Kunath, Frank; Coles, Bernadette; Draeger, Desiree Louise; Krabbe, Laura-Maria; Dersch, Rick; Kilian, Samuel; Jensen, Katrin; Dahm, Philipp; Meerpohl, Joerg J (8 January 2020). Cochrane Urology Group (ed.). "Intravesical Bacillus Calmette-Guérin versus mitomycin C for Ta and T1 bladder cancer". Cochrane Database of Systematic Reviews. 1 (1): CD011935. doi:10.1002/14651858.CD011935.pub2. PMC 6956215. PMID 31912907.
- ^ a b Zamboni S, Baumeister P, Mattei A, Mordasini L, Antonelli A, Simeone C, Moschini M (February 2019). "Single postoperative instillation for non-muscle invasive bladder cancer: are there still any indication?". Translational Andrology and Urology. 8 (1): 76–84. doi:10.21037/tau.2018.08.20. PMC 6414349. PMID 30976571.
- ^ Witjes JA, Hendricksen K (January 2008). "Intravesical pharmacotherapy for non-muscle-invasive bladder cancer: a critical analysis of currently available drugs, treatment schedules, and long-term results". European Urology. 53 (1): 45–52. doi:10.1016/j.eururo.2007.08.015. PMID 17719169.
- ^ Di Stasi SM, Riedl C (June 2009). "Updates in intravesical electromotive drug administration of mitomycin-C for non-muscle invasive bladder cancer" (PDF). World Journal of Urology. 27 (3): 325–30. doi:10.1007/s00345-009-0389-x. hdl:2108/6440. PMID 19234707. S2CID 24496739.
- ^ Kos B, Vásquez JL, Miklavčič D, Hermann GG, Gehl J (2016). "Investigation of the mechanisms of action behind Electromotive Drug Administration (EMDA)". PeerJ. 4 (e2309): e2309. doi:10.7717/peerj.2309. PMC 5012313. PMID 27635313.
- ^ Bahouth Z, Halachmi S, Moskovitz B, Nativ O (2016). "The role of hyperthermia as a treatment for non-muscle invasive bladder cancer". Expert Review of Anticancer Therapy. 16 (2): 189–98. doi:10.1586/14737140.2016.1126515. PMID 26618756. S2CID 681090.
- ^ Alexandroff AB, Jackson AM, O'Donnell MA, James K (May 1999). "BCG immunotherapy of bladder cancer: 20 years on". Lancet. 353 (9165): 1689–94. doi:10.1016/S0140-6736(98)07422-4. PMID 10335805. S2CID 19355109.
- ^ Lamm DL, Blumenstein BA, Crawford ED, Montie JE, Scardino P, Grossman HB, et al. (October 1991). "A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional-cell carcinoma of the bladder". The New England Journal of Medicine. 325 (17): 1205–9. doi:10.1056/NEJM199110243251703. PMID 1922207.
- ^ Kuroda K, Brown EJ, Telle WB, Russell DG, Ratliff TL (January 1993). "Characterization of the internalization of bacillus Calmette-Guerin by human bladder tumor cells". The Journal of Clinical Investigation. 91 (1): 69–76. doi:10.1172/JCI116202. PMC 329996. PMID 8423234.
- ^ Ratliff TL, Ritchey JK, Yuan JJ, Andriole GL, Catalona WJ (September 1993). "T-cell subsets required for intravesical BCG immunotherapy for bladder cancer". The Journal of Urology. 150 (3): 1018–23. doi:10.1016/s0022-5347(17)35678-1. PMID 8102183.
- ^ Fuge O, Vasdev N, Allchorne P, Green JS (2015). "Immunotherapy for bladder cancer". Research and Reports in Urology. 7: 65–79. doi:10.2147/RRU.S63447. PMC 4427258. PMID 26000263.
- ^ a b c d Kamat AM, Flaig TW, Grossman HB, Konety B, Lamm D, O'Donnell MA, et al. (April 2015). "Expert consensus document: Consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer". Nature Reviews. Urology. 12 (4): 225–35. doi:10.1038/nrurol.2015.58. PMID 25800393.
- ^ Alhunaidi O, Zlotta AR (2019). "The use of intravesical BCG in urothelial carcinoma of the bladder". ecancermedicalscience. 13: 905. doi:10.3332/ecancer.2019.905. PMC 6411413. PMID 30915163.
- ^ D'Andrea D, Gontero P, Shariat SF, Soria F (February 2019). "Intravesical bacillus Calmette-Guérin for bladder cancer: are all the strains equal?". Translational Andrology and Urology. 8 (1): 85–93. doi:10.21037/tau.2018.08.19. PMC 6414340. PMID 30976572.
- ^ Macleod LC, Ngo TC, Gonzalgo ML (July 2014). "Complications of intravesical bacillus calmette-guérin". Canadian Urological Association Journal. 8 (7–8): E540-4. doi:10.5489/cuaj.1411. PMC 4137021. PMID 25210559.
- ^ Shah S, Carter-Monroe N, Atta MG (October 2015). "Granulomatous interstitial nephritis". Clinical Kidney Journal. 8 (5): 516–23. doi:10.1093/ckj/sfv053. PMC 4581373. PMID 26413275.
- ^ Decaestecker K, Oosterlinck W (2015). "Managing the adverse events of intravesical bacillus Calmette-Guérin therapy". Research and Reports in Urology. 7: 157–63. doi:10.2147/RRU.S63448. PMC 4630183. PMID 26605208.
- ^ "ImmunityBio Announces FDA Approval of Anktiva, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer" (Press release). ImmunityBio. 23 April 2024. Retrieved 24 April 2024 – via Business Wire.
- ^ Witjes JA (May 2006). "Management of BCG failures in superficial bladder cancer: a review". European Urology. 49 (5): 790–7. doi:10.1016/j.eururo.2006.01.017. PMID 16464532. S2CID 5103506.
- ^ Babjuk W, Oosterlinck W, Sylvester R, et al. (2010). "Guidelines on TaT1 (Non-muscle invasive) Bladder Cancer". European Association of Urology. Archived from the original on 24 April 2010.
- ^ Bladder Cancer Clinical Guideline Update Panel (2007). Bladder Cancer: Guideline for the Management of Nonmuscle Invasive Bladder Cancer: (Stages Ta, T1, and Tis): 2007 Update. American Urological Association.[page needed]
- ^ Hassler MR, Shariat SF, Soria F (May 2019). "Salvage therapeutic strategies for bacillus Calmette-Guerin failure". Current Opinion in Urology. 29 (3): 239–246. doi:10.1097/MOU.0000000000000593. PMID 30762670. S2CID 73439134.
- ^ Moore, C (2006). "A clinical evaluation of the optical characteristics of the prostate in men with prostate cancer". European Urology. 5 (Suppl): 131.
- ^ Fleshker, S. (2008). "Photodynamic therapy for bladder cancer—a review of current status and future promise". Nature Reviews Urology. 84: 1231–1237. doi:10.1038/nrurol.2008.123 (inactive 29 April 2024).
{{cite journal}}
: CS1 maint: DOI inactive as of April 2024 (link) - ^ Limami, Youness (2023). "Shining a Light on Prostate Cancer: Photodynamic Therapy and Combination Approaches". Pharmaceutics. 15 (6): 1767. doi:10.3390/pharmaceutics15061767. PMC 10302598. PMID 37376215.
- ^ "Advances in Management of Bladder Cancer—The Role of Photodynamic Therapy". MDPI Pharmaceutics.
- ^ a b c d "Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline (2017) - American Urological Association". www.auanet.org. Archived from the original on 23 July 2020. Retrieved 20 November 2019.
- ^ a b c Hwang, Eu Chang; Sathianathen, Niranjan J; Imamura, Mari; Kuntz, Gretchen M; Risk, Michael C; Dahm, Philipp (14 May 2019). Cochrane Urology Group (ed.). "Extended versus standard lymph node dissection for urothelial carcinoma of the bladder in patients undergoing radical cystectomy". Cochrane Database of Systematic Reviews. 2019 (5): CD013336. doi:10.1002/14651858.CD013336. PMC 6528183. PMID 31111956.
- ^ Johar RS, Hayn MH, Stegemann AP, Ahmed K, Agarwal P, Balbay MD, et al. (July 2013). "Complications after robot-assisted radical cystectomy: results from the International Robotic Cystectomy Consortium". European Urology. 64 (1): 52–7. doi:10.1016/j.eururo.2013.01.010. PMID 23380164. S2CID 7369962.
- ^ Shabsigh A, Korets R, Vora KC, Brooks CM, Cronin AM, Savage C, et al. (January 2009). "Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology". European Urology. 55 (1): 164–74. doi:10.1016/j.eururo.2008.07.031. PMID 18675501.
- ^ Moschini M, Simone G, Stenzl A, Gill IS, Catto J (April 2016). "Critical Review of Outcomes from Radical Cystectomy: Can Complications from Radical Cystectomy Be Reduced by Surgical Volume and Robotic Surgery?". European Urology Focus. 2 (1): 19–29. doi:10.1016/j.euf.2016.03.001. PMID 28723446.
- ^ Cerantola Y, Valerio M, Persson B, Jichlinski P, Ljungqvist O, Hubner M, et al. (December 2013). "Guidelines for perioperative care after radical cystectomy for bladder cancer: Enhanced Recovery After Surgery (ERAS(®)) society recommendations". Clinical Nutrition. 32 (6): 879–87. doi:10.1016/j.clnu.2013.09.014. PMID 24189391. S2CID 24108744.
- ^ "UpToDate: Neoadjuvant chemotherapy". www.uptodate.com.
- ^ Vale, C. (June 2003). "Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis". Lancet. 361 (9373): 1927–34. doi:10.1016/s0140-6736(03)13580-5. PMID 12801735. S2CID 29233494.
- ^ Advanced Bladder Cancer (ABC) Meta-analysis Collaboration (August 2005). "Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration". European Urology. 48 (2): 202–5, discussion 205–6. doi:10.1016/j.eururo.2005.04.006. PMID 15939524.
- ^ Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL, et al. (August 2003). "Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer". The New England Journal of Medicine. 349 (9): 859–66. doi:10.1056/NEJMoa022148. PMID 12944571.
- ^ a b Yin M, Joshi M, Meijer RP, Glantz M, Holder S, Harvey HA, et al. (June 2016). "Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: A Systematic Review and Two-Step Meta-Analysis". The Oncologist. 21 (6): 708–15. doi:10.1634/theoncologist.2015-0440. PMC 4912364. PMID 27053504.
- ^ Iwata T, Kimura S, Abufaraj M, Janisch F, Karakiewicz PI, Seebacher V, et al. (October 2019). "The role of adjuvant radiotherapy after surgery for upper and lower urinary tract urothelial carcinoma: A systematic review". Urologic Oncology. 37 (10): 659–671. doi:10.1016/j.urolonc.2019.05.021. PMID 31255542. S2CID 195760627.
- ^ a b c d "Bladder Cancer Treatment Regimens". Cancer Therapy Advisor. 1 January 2019. Archived from the original on 29 August 2021. Retrieved 26 November 2019.
- ^ "UpToDate". www.uptodate.com. Retrieved 26 November 2019.
- ^ a b c Ploussard G, Daneshmand S, Efstathiou JA, Herr HW, James ND, Rödel CM, et al. (July 2014). "Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review". European Urology. 66 (1): 120–37. doi:10.1016/j.eururo.2014.02.038. PMID 24613684.
- ^ Smelser WW, Austenfeld MA, Holzbeierlein JM, Lee EK. Where are we with bladder preservation for muscle-invasive bladder cancer in 2017?. Indian J Urol 2017;33:111–7 http://www.indianjurol.com/text.asp?2017/33/2/111/203415 Archived 10 September 2017 at the Wayback Machine
- ^ Mirza A, Choudhury A (April 2016). "Bladder Preservation for Muscle Invasive Bladder Cancer". Bladder Cancer. 2 (2): 151–163. doi:10.3233/BLC-150025. PMC 4927909. PMID 27376137.
- ^ "Chemotherapy for Bladder Cancer". www.cancer.org. Retrieved 27 November 2019.
- ^ Klaile Y, Schlack K, Boegemann M, Steinestel J, Schrader AJ, Krabbe LM (October 2016). "Variant histology in bladder cancer: how it should change the management in non-muscle invasive and muscle invasive disease?". Translational Andrology and Urology. 5 (5): 692–701. doi:10.21037/tau.2016.06.13. PMC 5071184. PMID 27785426.
- ^ "EAU Guidelines: Muscle-invasive and Metastatic Bladder Cancer". Uroweb.
- ^ Galsky MD, Hahn NM, Rosenberg J, Sonpavde G, Hutson T, Oh WK, et al. (June 2011). "Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapy". Journal of Clinical Oncology. 29 (17): 2432–8. doi:10.1200/JCO.2011.34.8433. PMID 21555688. S2CID 33263969.
- ^ a b Keam B (2018). "Section VI. Chemotherapy for Metastatic Bladder Cancer". Bladder Cancer. Academic Press. p. 527. ISBN 978-0-12-809939-1. Retrieved 27 November 2019.
- ^ Lyman GH, Dale DC, Culakova E, Poniewierski MS, Wolff DA, Kuderer NM, et al. (October 2013). "The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trials". Annals of Oncology. 24 (10): 2475–84. doi:10.1093/annonc/mdt226. PMC 3841419. PMID 23788754.
- ^ Gilligan TD, Steele GS, Zietman AL, Kantoff PW (2003). Chemotherapy for Metastatic Disease. BC Decker.
- ^ Galsky MD, Chen GJ, Oh WK, Bellmunt J, Roth BJ, Petrioli R, et al. (February 2012). "Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma". Annals of Oncology. 23 (2): 406–10. doi:10.1093/annonc/mdr156. PMID 21543626.
- ^ Shelley MD, Cleves A, Wilt TJ, Mason MD (July 2011). "Gemcitabine chemotherapy for the treatment of metastatic bladder carcinoma". BJU International. 108 (2): 168–79. doi:10.1111/j.1464-410X.2011.10341.x. PMID 21718430. S2CID 26003400.
- ^ Aapro M, Abrahamsson PA, Body JJ, Coleman RE, Colomer R, Costa L, et al. (March 2008). "Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel". Annals of Oncology. 19 (3): 420–32. doi:10.1093/annonc/mdm442. PMID 17906299.
- ^ Sridhar SS (May 2017). "Evolving Treatment of Advanced Urothelial Cancer". Journal of Oncology Practice. 13 (5): 309–315. doi:10.1200/JOP.2017.022137. PMID 28489981.
- ^ Gerullis H, Wawroschek F, Köhne CH, Ecke TH (January 2017). "Vinflunine in the treatment of advanced urothelial cancer: clinical evidence and experience". Therapeutic Advances in Urology. 9 (1): 28–35. doi:10.1177/1756287216677903. PMC 5167074. PMID 28042310.
- ^ Oing C, Rink M, Oechsle K, Seidel C, von Amsberg G, Bokemeyer C (February 2016). "Second Line Chemotherapy for Advanced and Metastatic Urothelial Carcinoma: Vinflunine and Beyond-A Comprehensive Review of the Current Literature". The Journal of Urology. 195 (2): 254–63. doi:10.1016/j.juro.2015.06.115. PMID 26410730.
- ^ Keam B (2018). "Section VI. Chemotherapy for Metastatic Bladder Cancer". Bladder Cancer. Academic Press. p. 530. ISBN 978-0-12-809939-1. Retrieved 27 November 2019.
- ^ "Erdafitinib Effective Against Advanced Bladder Cancer". National Cancer Institute. 9 August 2019.
- ^ Konala VM, Adapa S, Aronow WS (February 2019). "Immunotherapy in Bladder Cancer". American Journal of Therapeutics. 29 (3): e334–e337. doi:10.1097/MJT.0000000000000934. PMID 30839322. S2CID 73472390.
- ^ Katz H, Wassie E, Alsharedi M (September 2017). "Checkpoint inhibitors: the new treatment paradigm for urothelial bladder cancer". Medical Oncology. 34 (10): 170. doi:10.1007/s12032-017-1029-8. PMID 28864844. S2CID 22280860.
- ^ a b c Narayan, Vikram; Kahlmeyer, Andreas; Dahm, Philipp; Skoetz, Nicole; Risk, Michael C; Bongiorno, Connie; Patel, Neil; Hwang, Eu Chang; Jung, Jae Hung; Gartlehner, Gerald; Kunath, Frank (23 July 2018). Cochrane Urology Group (ed.). "Pembrolizumab monotherapy versus chemotherapy for treatment of advanced urothelial carcinoma with disease progression during or following platinum-containing chemotherapy. A Cochrane Rapid Review". Cochrane Database of Systematic Reviews. 2018 (7): CD012838. doi:10.1002/14651858.CD012838.pub2. PMC 6513246. PMID 30036453.
- ^ Heidenreich A, Albers P, Classen J, Graefen M, Gschwend J, Kotzerke J, et al. (2010). "Imaging studies in metastatic urogenital cancer patients undergoing systemic therapy: recommendations of a multidisciplinary consensus meeting of the Association of Urological Oncology of the German Cancer Society". Urologia Internationalis. 85 (1): 1–10. doi:10.1159/000318985. PMID 20693823.
- ^ Llewelyn R. "Response evaluation criteria in solid tumors | Radiology Reference Article | Radiopaedia.org". Radiopaedia.
- ^ "What Causes Bladder Cancer?". American Cancer Society. 12 March 2024. Retrieved 2 July 2024.
- ^ Zeegers MP, Tan FE, Dorant E, van Den Brandt PA (August 2000). "The impact of characteristics of cigarette smoking on urinary tract cancer risk: a meta-analysis of epidemiologic studies". Cancer. 89 (3): 630–9. doi:10.1002/1097-0142(20000801)89:3<630::AID-CNCR19>3.0.CO;2-Q. PMID 10931463.
- ^ a b van Osch FH, Jochems SH, van Schooten FJ, Bryan RT, Zeegers MP (June 2016). "Quantified relations between exposure to tobacco smoking and bladder cancer risk: a meta-analysis of 89 observational studies". International Journal of Epidemiology. 45 (3): 857–70. doi:10.1093/ije/dyw044. PMID 27097748.
- ^ Letašiová S, Medve'ová A, Šovčíková A, Dušinská M, Volkovová K, Mosoiu C, Bartonová A (June 2012). "Bladder cancer, a review of the environmental risk factors". Environmental Health. 11 (Suppl 1): S11. Bibcode:2012EnvHe..11S..11L. doi:10.1186/1476-069X-11-S1-S11. PMC 3388449. PMID 22759493.
- ^ Brennan P, Bogillot O, Cordier S, Greiser E, Schill W, Vineis P, et al. (April 2000). "Cigarette smoking and bladder cancer in men: a pooled analysis of 11 case-control studies". International Journal of Cancer. 86 (2): 289–94. doi:10.1002/(sici)1097-0215(20000415)86:2<289::aid-ijc21>3.0.co;2-m. PMID 10738259.
- ^ Yan H, Ying Y, Xie H, Li J, Wang X, He L, et al. (2018). "Secondhand smoking increases bladder cancer risk in nonsmoking population: a meta-analysis". Cancer Management and Research. 10: 3781–3791. doi:10.2147/CMAR.S175062. PMC 6159806. PMID 30288109.
- ^ "Health Risks of Secondhand Smoke". www.cancer.org. Retrieved 21 November 2019.
- ^ Afshari M, Janbabaei G, Bahrami MA, Moosazadeh M (2017). "Opium and bladder cancer: A systematic review and meta-analysis of the odds ratios for opium use and the risk of bladder cancer". PLOS ONE. 12 (6): e0178527. Bibcode:2017PLoSO..1278527A. doi:10.1371/journal.pone.0178527. PMC 5460843. PMID 28586371.
- ^ IARC Working Group on the Evaluation of Carcinogenic Risk to Humans (2012). 4-AMINOBIPHENYL. International Agency for Research on Cancer.
- ^ Saint-Jacques N, Parker L, Brown P, Dummer TJ (June 2014). "Arsenic in drinking water and urinary tract cancers: a systematic review of 30 years of epidemiological evidence". Environmental Health. 13 (1): 44. Bibcode:2014EnvHe..13...44S. doi:10.1186/1476-069X-13-44. PMC 4088919. PMID 24889821.
- ^ Clin B, Pairon JC (November 2014). "Medical follow-up for workers exposed to bladder carcinogens: the French evidence-based and pragmatic statement". BMC Public Health. 14: 1155. doi:10.1186/1471-2458-14-1155. PMC 4230399. PMID 25377503.
- ^ IARC Working Group on the Evaluation of Carcinogenic Risk to Humans (2012). CHLORNAPHAZINE. International Agency for Research on Cancer.
- ^ Humans, IARC Working Group on the Evaluation of Carcinogenic Risk to (2012). 2-NAPHTHYLAMINE. International Agency for Research on Cancer.
- ^ Reulen RC, Kellen E, Buntinx F, Brinkman M, Zeegers MP (September 2008). "A meta-analysis on the association between bladder cancer and occupation". Scandinavian Journal of Urology and Nephrology. Supplementum. 42 (218): 64–78. doi:10.1080/03008880802325192. PMID 18815919. S2CID 30510231.
- ^ Guha N, Steenland NK, Merletti F, Altieri A, Cogliano V, Straif K (August 2010). "Bladder cancer risk in painters: a meta-analysis". Occupational and Environmental Medicine. 67 (8): 568–73. doi:10.1136/oem.2009.051565. PMID 20647380.
- ^ Harling M, Schablon A, Schedlbauer G, Dulon M, Nienhaus A (May 2010). "Bladder cancer among hairdressers: a meta-analysis". Occupational and Environmental Medicine. 67 (5): 351–8. doi:10.1136/oem.2009.050195. PMC 2981018. PMID 20447989.
- ^ Mostafa MH, Sheweita SA, O'Connor PJ (January 1999). "Relationship between schistosomiasis and bladder cancer". Clinical Microbiology Reviews. 12 (1): 97–111. doi:10.1128/CMR.12.1.97. PMC 88908. PMID 9880476.
- ^ Zaghloul MS (December 2012). "Bladder cancer and schistosomiasis". Journal of the Egyptian National Cancer Institute. 24 (4): 151–9. doi:10.1016/j.jnci.2012.08.002. PMID 23159285.
- ^ Mostafa MH, Helmi S, Badawi AF, Tricker AR, Spiegelhalder B, Preussmann R (April 1994). "Nitrate, nitrite and volatile N-nitroso compounds in the urine of Schistosoma haematobium and Schistosoma mansoni infected patients". Carcinogenesis. 15 (4): 619–25. doi:10.1093/carcin/15.4.619. PMID 8149471.
- ^ Badawi AF (August 1996). "Molecular and genetic events in schistosomiasis-associated human bladder cancer: role of oncogenes and tumor suppressor genes". Cancer Letters. 105 (2): 123–38. doi:10.1016/0304-3835(96)04284-x. PMID 8697435.
- ^ Chaudhary KS, Lu QL, Abel PD, Khandan-Nia N, Shoma AM, el Baz M, et al. (January 1997). "Expression of bcl-2 and p53 oncoproteins in schistosomiasis-associated transitional and squamous cell carcinoma of urinary bladder". British Journal of Urology. 79 (1): 78–84. doi:10.1046/j.1464-410x.1997.30717.x. PMID 9043502.
- ^ Shokeir AA (January 2004). "Squamous cell carcinoma of the bladder: pathology, diagnosis and treatment". BJU International. 93 (2): 216–20. doi:10.1111/j.1464-410x.2004.04588.x. PMID 14690486. S2CID 10487371.
- ^ Monach PA, Arnold LM, Merkel PA (January 2010). "Incidence and prevention of bladder toxicity from cyclophosphamide in the treatment of rheumatic diseases: a data-driven review". Arthritis and Rheumatism. 62 (1): 9–21. doi:10.1002/art.25061. PMID 20039416.
- ^ "Diet, nutrition, physical activity and bladder cancer". wcrf.org. Retrieved 27 October 2022.
- ^ a b Dianatinasab, Mostafa; Wesselius, Anke; Salehi-Abargouei, Amin; Yu, Evan Y. W; Fararouei, Mohammad; Brinkman, Maree; Brandt, Piet van den; White, Emily; Weiderpass, Elisabete; Calvez-Kelm, Florence Le; Gunter, Marc J; Huybrechts, Inge; Zeegers, Maurice P. (2022). "Dietary fats and their sources in association with the risk of bladder cancer: A pooled analysis of 11 prospective cohort studies". International Journal of Cancer. 151 (1): 44–55. doi:10.1002/ijc.33970. PMC 9303525. PMID 35182086.
{{cite journal}}
: CS1 maint: multiple names: authors list (link) - ^ Yang HY, Chen PC, Wang JD (2014). "Chinese herbs containing aristolochic acid associated with renal failure and urothelial carcinoma: a review from epidemiologic observations to causal inference". BioMed Research International. 2014: 569325. doi:10.1155/2014/569325. PMC 4241283. PMID 25431765.
- ^ Suriano F, Altobelli E, Sergi F, Buscarini M (2013). "Bladder cancer after radiotherapy for prostate cancer". Reviews in Urology. 15 (3): 108–12. PMC 3821989. PMID 24223022.
- ^ Sun JW, Zhao LG, Yang Y, Ma X, Wang YY, Xiang YB (24 March 2015). "Obesity and risk of bladder cancer: a dose-response meta-analysis of 15 cohort studies". PLOS ONE. 10 (3): e0119313. Bibcode:2015PLoSO..1019313S. doi:10.1371/journal.pone.0119313. PMC 4372289. PMID 25803438.
- ^ Al-Zalabani AH, Stewart KF, Wesselius A, Schols AM, Zeegers MP (September 2016). "Modifiable risk factors for the prevention of bladder cancer: a systematic review of meta-analyses". European Journal of Epidemiology. 31 (9): 811–51. doi:10.1007/s10654-016-0138-6. PMC 5010611. PMID 27000312.
- ^ "Cancer Genetics Browser". cancer.sanger.ac.uk. Retrieved 21 November 2019.
- ^ Online Mendelian Inheritance in Man (OMIM): 109800
- ^ Zhang X, Zhang Y (September 2015). "Bladder Cancer and Genetic Mutations". Cell Biochemistry and Biophysics. 73 (1): 65–9. doi:10.1007/s12013-015-0574-z. PMID 27352265. S2CID 14316154.
- ^ "Bladder cancer". Genetics Home Reference.
- ^ Ahmad I, Sansom OJ, Leung HY (May 2012). "Exploring molecular genetics of bladder cancer: lessons learned from mouse models". Disease Models & Mechanisms. 5 (3): 323–32. doi:10.1242/dmm.008888. PMC 3339826. PMID 22422829.
- ^ Humphrey PA, Moch H, Cubilla AL, Ulbright TM, Reuter VE (July 2016). "The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part B: Prostate and Bladder Tumours" (PDF). European Urology. 70 (1): 106–119. doi:10.1016/j.eururo.2016.02.028. PMID 26996659. S2CID 3756845.
- ^ Engel LS, Taioli E, Pfeiffer R, Garcia-Closas M, Marcus PM, Lan Q, et al. (July 2002). "Pooled analysis and meta-analysis of glutathione S-transferase M1 and bladder cancer: a HuGE review". American Journal of Epidemiology. 156 (2): 95–109. doi:10.1093/aje/kwf018. PMID 12117698.
- ^ a b c "Bladder Cancer Report" (PDF). World Cancer Research Fund : International. Retrieved 9 November 2019.
- ^ a b c Marks P, Soave A, Shariat SF, Fajkovic H, Fisch M, Rink M (October 2016). "Female with bladder cancer: what and why is there a difference?". Translational Andrology and Urology. 5 (5): 668–682. doi:10.21037/tau.2016.03.22. PMC 5071204. PMID 27785424.
- ^ Choi W, Ochoa A, McConkey DJ, Aine M, Höglund M, Kim WY, et al. (September 2017). "Genetic Alterations in the Molecular Subtypes of Bladder Cancer: Illustration in the Cancer Genome Atlas Dataset". European Urology. 72 (3): 354–365. doi:10.1016/j.eururo.2017.03.010. PMC 5764190. PMID 28365159.
- ^ Choi W, Czerniak B, Ochoa A, Su X, Siefker-Radtke A, Dinney C, McConkey DJ (July 2014). "Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer". Nature Reviews. Urology. 11 (7): 400–10. doi:10.1038/nrurol.2014.129. PMID 24960601. S2CID 24723395.
- ^ Dianatinasab, M., Forozani, E., Akbari, A. (2022). "Dietary patterns and risk of bladder cancer: a systematic review and meta-analysis". BMC Public Health. 22 (1): 73. doi:10.1186/s12889-022-12516-2. PMC 8753903. PMID 35016647.
{{cite journal}}
: CS1 maint: multiple names: authors list (link) - ^ Yu EYW, Wesselius A, Mehrkanoon S, Brinkman M, van den Brandt P, White E, Weiderpass E, Le Calvez-Kelm F, Gunter M, Huybrechts I, Liedberg F, Skeie G, Tjonneland A, Riboli E, Giles GG, Milne RL, Zeegers MP (2020). "Grain and dietary fiber intake and bladder cancer risk: a pooled analysis of prospective cohort studies". The American Journal of Clinical Nutrition. 112 (5): 1252–1266. doi:10.1093/ajcn/nqaa215. PMC 7657329. PMID 32778880.
{{cite journal}}
: CS1 maint: multiple names: authors list (link) - ^ "Final Update Summary: Bladder Cancer in Adults: Screening - US Preventive Services Task Force". www.uspreventiveservicestaskforce.org. Retrieved 13 November 2019.
- ^ Siddiqui MR, Grant C, Sanford T, Agarwal PK (August 2017). "Current clinical trials in non-muscle invasive bladder cancer". Urologic Oncology. 35 (8): 516–527. doi:10.1016/j.urolonc.2017.06.043. PMC 5556973. PMID 28778250.
- ^ "Bladder Cancer - Statistics". Cancer.Net. 25 June 2012.
- ^ Kaufman DS, Shipley WU, Feldman AS (July 2009). "Bladder cancer". Lancet. 374 (9685): 239–49. doi:10.1016/S0140-6736(09)60491-8. PMID 19520422. S2CID 40417997.
- ^ van der Heijden AG, Witjes JA (September 2009). "Recurrence, Progression, and Follow-Up in Non–Muscle-Invasive Bladder Cancer". European Urology Supplements. 8 (7): 556–562. doi:10.1016/j.eursup.2009.06.010.
- ^ Tyson MD, Chang SS, Keegan KA (2016). "Role of consolidative surgical therapy in patients with locally advanced or regionally metastatic bladder cancer". Bladder. 3 (2): e26. doi:10.14440/bladder.2016.89 (inactive 29 April 2024). PMC 5336315. PMID 28261632.
{{cite journal}}
: CS1 maint: DOI inactive as of April 2024 (link) - ^ Zhang L, Wu B, Zha Z, Qu W, Zhao H, Yuan J (July 2019). "Clinicopathological factors in bladder cancer for cancer-specific survival outcomes following radical cystectomy: a systematic review and meta-analysis". BMC Cancer. 19 (1): 716. doi:10.1186/s12885-019-5924-6. PMC 6642549. PMID 31324162.
- ^ Ku JH, Kang M, Kim HS, Jeong CW, Kwak C, Kim HH (June 2015). "Lymph node density as a prognostic variable in node-positive bladder cancer: a meta-analysis". BMC Cancer. 15: 447. doi:10.1186/s12885-015-1448-x. PMC 4450458. PMID 26027955.
- ^ Yang LS, Shan BL, Shan LL, Chin P, Murray S, Ahmadi N, Saxena A (September 2016). "A systematic review and meta-analysis of quality of life outcomes after radical cystectomy for bladder cancer". Surgical Oncology. 25 (3): 281–97. doi:10.1016/j.suronc.2016.05.027. PMID 27566035.
- ^ Somani BK, Gimlin D, Fayers P, N'dow J (November 2009). "Quality of life and body image for bladder cancer patients undergoing radical cystectomy and urinary diversion--a prospective cohort study with a systematic review of literature". Urology. 74 (5): 1138–43. doi:10.1016/j.urology.2009.05.087. PMID 19773042.
- ^ Vartolomei L, Ferro M, Mirone V, Shariat SF, Vartolomei MD (July 2018). "Systematic Review: Depression and Anxiety Prevalence in Bladder Cancer Patients". Bladder Cancer. 4 (3): 319–326. doi:10.3233/BLC-180181. PMC 6087432. PMID 30112443.
- ^ David E (February 2017). "Psychiatric disorders worsen bladder cancer survival". www.healio.com. Retrieved 27 November 2019.
- ^ Correa AF, Smaldone MC (August 2018). "Melancholia and cancer: The bladder cancer narrative". Cancer. 124 (15): 3080–3083. doi:10.1002/cncr.31402. PMID 29660788.
- ^ "Bladder cancer statistics". World Cancer Research Fund. 22 August 2018. Retrieved 9 November 2019.
- ^ "Greece Factsheet" (PDF). Global Cancer Observatory. Retrieved 9 November 2019.
- ^ "WHO Disease and injury country estimates". World Health Organization. 2009. Archived from the original on 11 November 2009. Retrieved 11 November 2009.
- ^ Lenis, Lec & Chamie 2020, p. 1980.
- ^ a b Dyrskjøt et al. 2023, "Epidemiology".
- ^ a b Dyrskjøt et al. 2023, "Introduction".
- ^ a b Hemelt M, Yamamoto H, Cheng KK, Zeegers MP (January 2009). "The effect of smoking on the male excess of bladder cancer: a meta-analysis and geographical analyses". International Journal of Cancer. 124 (2): 412–9. doi:10.1002/ijc.23856. PMID 18792102. S2CID 28518800.
- ^ Hahn 2022, "Introduction".
- ^ Lipscomb, Victoria J. (2011). "Section XI Urogenital system. Chapter 116 Bladder. Bladder neoplasia". In Tobias, Karen M.; Johnston, Spencer A. (eds.). Veterinary Surgery. London: Elsevier Health Sciences. pp. 1990–1992. ISBN 9780323263375.
Works cited
[edit]- Ahmadi H, Duddalwar V, Daneshmand S (June 2021). "Diagnosis and Staging of Bladder Cancer". Hematol Oncol Clin North Am. 35 (3): 531–541. doi:10.1016/j.hoc.2021.02.004. PMID 33958149.
- Dyrskjøt L, Hansel DE, Efstathiou JA, Knowles MA, Galsky MD, Teoh J, Theodorescu D (October 2023). "Bladder cancer". Nat Rev Dis Primers. 9 (1): 58. doi:10.1038/s41572-023-00468-9. PMC 11218610. PMID 37884563.
- Hahn NM (2022). "Chapter 86: Cancer of the Bladder and Urinary Tract". In Loscalzo J, Fauci A, Kasper D, et al. (eds.). Harrison's Principles of Internal Medicine (21st ed.). McGraw Hill. ISBN 978-1264268504.
- Lenis AT, Lec PM, Chamie K (November 2020). "Bladder Cancer: A Review". JAMA. 324 (19): 1980–1991. doi:10.1001/jama.2020.17598. PMID 33201207.